



LKT Laboratories, Inc.

Afatinib

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A2077

CAS No. 850140-72-6

Chemical Name N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazoliny]-4(dimethylamino)-2-butenamide

Synonym BIBW 2992

Formula C₂₄H₂₅ClFN₅O₃

Formula Wt. 485.94

Melting Point 130-142 °C


Purity ≥98%

Solubility

Store Temp 4 °C

Ship Temp Ambient

Description Afatinib is an anticancer chemotherapeutic compound that has been approved to treat advanced lung cancers such as non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for other advanced solid tumors such as breast cancer and colorectal cancer. Afatinib exerts its anticancer activity through inhibition of EGFR and EGFR2 (HER2/ErbB2). In vivo, afatinib downregulates expression of HER2, increasing apoptosis and decreasing tumor size.



Bulk quantities available upon request

Product ID	Size
A2077	5 mg
A2077	10 mg
A2077	25 mg
A2077	100 mg

References Yap TA, Popat S. The role of afatinib in the management of non-small cell lung carcinoma. *Expert Opin Drug Metab Toxicol.* 2013 Nov;9(11):1529-39. PMID: 23985030.

Janjigian YY, Viola-Villegas N, Holland JP, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. *J Nucl Med.* 2013 Jun;54(6):936-43. PMID: 23578997.

Solca F, Dahl G, Zoepfel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. *J Pharmacol Exp Ther.* 2012 Nov;343(2):342-50. PMID: 22888144.

Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. *Future Oncol.* 2011 Jul;7(7):817-25. PMID: 21732753.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.